LY 3053102

Drug Profile

LY 3053102

Alternative Names: LY-3053102

Latest Information Update: 23 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 23 Dec 2015 Discontinued - Phase-I for Type-2 diabetes mellitus (In volunteers) in Singapore (SC)
  • 23 Dec 2015 Discontinued - Phase-I/II for Type-2 diabetes mellitus in USA (SC)
  • 24 Feb 2015 Eli Lilly terminates a phase I/II trial for Type-2 diabetes mellitus in USA (NCT02020616)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top